Table 3 Univariable and multivariable cox analysis of DFS before propensity matched analysis
Variable | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
Age (≥60/< 60, year) | 1.240 | 0.765–2.010 | 0.382 | – | – | – |
Sex (Men/Women) | 1.751 | 1.042–2.941 | 0.034 | 1.919 | 1.097–3.357 | 0.022 |
HBsAg (yes/no) | 0.672 | 0.405–1.114 | 0.123 | – | – | – |
HCV antibody (yes/no) | 0.782 | 0.108–5.636 | 0.807 | – | – | – |
AFP (≥20/< 20, ng/mL) | 1.245 | 0.824–1.881 | 0.299 | – | – | – |
CEA (≥5/<5, ng/mL) | 1.169 | 0.672–2.035 | 0.581 | – | – | – |
CA19–9 (≥37/<37, U/mL) | 1.136 | 0.727–1.775 | 0.575 | – | – | – |
Liver cirrhosis, yes (%) | 1.291 | 0.815–2.044 | 0.277 | – | – | – |
TB (≥17/< 17, μmol/L) | 0.998 | 0.607–1.641 | 0.995 | – | – | – |
ALB (≥40/<40, g/mL) | 0.771 | 0.499–1.191 | 0.241 | – | – | – |
ALT (≥35/<35, U/L) | 1.741 | 1.154–2.267 | 0.008 | 1.676 | 1.050–2.677 | 0.031 |
γ-GT (≥40/<40, U/L) | 1.811 | 1.116–2.938 | 0.016 | 1.105 | 0.653–1.870 | 0.711 |
PLT (≥10/< 10 103/μL) | 0.856 | 0.529–1.382 | 0.524 | – | – | – |
Prothrombin time, median (range), s | 1.417 | 0.845–2.375 | 0.186 | – | – | – |
Tumour size, cm | 1.226 | 0.809–1.857 | 0.338 | – | – | – |
Tumour nodularities | 1.056 | 0.918–1.215 | 0.442 | – | – | – |
Occlusion, min (< 20/≥20) | 2.363 | 1.356–4.119 | 0.002 | 1.790 | 0.974–3.289 | 0.061 |
Macrovascular invasion (yes/no) | 1.878 | 1.300–2.713 | 0.001 | 2.026 | 1.342–3.058 | 0.001 |
Microvascular invasion (yes/no) | 1.084 | 0.654–1.797 | 0.754 | – | – | – |
Lymphoid metastasis (yes/no) | 2.300 | 1.287–4.112 | 0.005 | 2.835 | 1.517–5.297 | 0.001 |
Extrahepatic metastasis (yes/no) | 2.248 | 0.538–9.395 | 0.267 | – | – | – |
Preventive TACE (yes/no) | 2.799 | 1.815–4.317 | < 0.001 | 2.763 | 1.769–4.314 | < 0.001 |